RSV Vaccine │ Vaccine Trial │ Phase I │California

RSV Vaccine Clinical Trial

FOMAT is enrolling participants for RSV Vaccine Trial

Respiratory syncytial (sin-SISH-uhl) virus, or RSV, is a common respiratory virus that usually causes mild, cold-like symptoms. Most people recover in a week or two, but RSV can be serious, especially for infants and older adults.

Are you 60 years or older and interested in an RSV Vaccine? Then consider joining this paid clinical trial!

What is RSV?

RSV can also make chronic health problems worse. For example, people with asthma may experience asthma attacks as a result of RSV infection, and people with congestive heart failure may experience more severe symptoms triggered by RSV.

RSV Transmission

RSV can spread when An infected person coughs or sneezes You get virus droplets from a cough or sneeze in your eyes, nose, or mouth You touch a surface that has the virus on it, like a doorknob, and then touch your face before washing your hands You have direct contact with the virus, like kissing the face of a child with RSV People infected with RSV are usually contagious for 3 to 8 days.

However, some infants, and people with weakened immune systems, can continue to spread the virus even after they stop showing symptoms, for as long as 4 weeks.

Children are often exposed to and infected with RSV outside the home, such as in school or child-care centers. They can then transmit the virus to other members of the family.

RSV can survive for many hours on hard surfaces such as tables and crib rails. It typically lives on soft surfaces such as tissues and hands for shorter amounts of time.

RSV in Older Adults

RSV infections can be dangerous for certain adults. Each year, it is estimated that more than 177,000 older adults are hospitalized and 14,000 of them die in the United States due to RSV infection.

Older adults are at greater risk for serious complications from RSV because their immune systems are weaker as they grow older.

Adults at the highest risk for severe RSV infection include

Older adults, especially those 65 years and older
Adults with chronic heart or lung disease
Adults with weakened immune systems

Source: CDC.gov

Study Compensation

You will be compensated for your time in the study. You will receive ≥$50 after each completed visit. The study drug will be provided to you at no charge and you will not be charged for any procedure performed for this study.

You will be reimbursed following each completed visit.